Retinitis Pigmentosa – Epidemiology – Mature Markets Data

Clarivate’s Epidemiology’s coverage of RP comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report the diagnosed prevalence of RP for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets of the United States, Europe and Japan in this report.

Clarivate’s Epidemiology’s RP forecast will answer the following questions:

  • Of all people diagnosed with RP, how many in each country across the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of RP over the forecast period?

All forecast data are available on the Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate’s Epidemiology provides at least ten years of forecast data for the following RP patient populations:

  • Diagnosed Prevalent Cases of Inherited Retinal Dystrophy
  • Diagnosed Prevalent Cases of RetinitisPigmentosa
  • Drug-Treated Prevalent Cases of RetinitisPigmentosa
  • Clinical Subtypes of RetinitisPigmentosa
  • Diagnosed Prevalent Cases of Usher Syndrome
  • Diagnosed Prevalent Cases of Bardet-Biedl Syndrome
  • Diagnosed Prevalent Cases with RPE65Mutation
  • Diagnosed Prevalent Cases of Leber’s Congenital Amaurosis
  • Diagnosed Prevalent Cases of Choroideremia

Note: coverage may vary by country and region.

Table of contents